Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company.
Parry considers the combination of new products, consumer health and vaccines as having the ability to balance out the "diminishing heawind of diabetes." (See his track record here.)
The analyst said he has growing confidence in the following growth drivers for Sanofi:
- Dupixent's strong launch in dermatitis.
- Expectations of 4-percent consumer growth in 2019.
- A recovery in vaccines this year on the basis of a resolution of manufacturing issues in China.
“We expect diabetes to become less of a headwind into 2019 and beyond, declining 6-percent [in 2019] vs. 13 percent in 2017-18," Parry said.
"Although price pressure for U.S. Lantus has not abated, additional biosimilars may launch [in] 2019/20, and we continue to forecast 20-30-percent year-over-year sales declines going forwards, it now only represents 3 percent of 2019 group sales vs. 13 percent in 2014. We expect growth in other regions [and] products to increasingly offset."
Sanofi shares were up 1.2 percent at $42.60 before the close Monday.
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
Latest Ratings for SNY
|Sep 2018||Bank of America||Upgrades||Neutral||Buy|
View More Analyst Ratings for SNY
View the Latest Analyst Ratings
See more from Benzinga
- BTIG Downgrades Zscaler On Valuation, Says Company Is Redefining Cybersecurity Market
- DA Davidson Upgrades Akamai: 'Revenue From New Products Has Tripled In Just The Last Year'
- Applebee's Parent Dine Brands Downgraded By Raymond James After 30% Rally
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.